Acrivon Therapeutics Inc.... (ACRV)
1.85
-0.30 (-13.95%)
At close: Apr 16, 2025, 9:56 AM
-13.95% (1D)
| Bid | 1.83 |
| Market Cap | 58M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -80.56M |
| EPS (ttm) | -2.38 |
| PE Ratio (ttm) | -0.78 |
| Forward PE | -0.83 |
| Analyst | Buy |
| Ask | 2.38 |
| Volume | 199,041 |
| Avg. Volume (20D) | 156,078 |
| Open | 2.15 |
| Previous Close | 2.15 |
| Day's Range | 1.83 - 2.18 |
| 52-Week Range | 1.30 - 11.51 |
| Beta | 1.78 |
About ACRV
Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics tha...
Industry Biotechnology
Sector Healthcare
IPO Date Nov 15, 2022
Employees 75
Stock Exchange NASDAQ
Ticker Symbol ACRV
Website https://www.acrivon.com
Analyst Forecast
According to 7 analyst ratings, the average rating for ACRV stock is "Buy." The 12-month stock price forecast is $18, which is an increase of 872.97% from the latest price.
Stock Forecasts2 weeks ago
-51.58%
Acrivion Therapeutics shares are trading lower aft...
Unlock content with
Pro Subscription
2 months ago
+17.94%
Acrivon Therapeutics shares are trading higher after the company announced it was granted FDA breakthrough device designation for ACR 368 OncoSignature Assay.
